Related Experiment Video
Updated: Feb 15, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based
Giandomenico Roviello1,2, Daniele Generali3,4
1Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Via Padre Pio 1, 85028, Rionero in Vulture, PZ, Italy. giandomenicoroviello@hotmail.it.
Abstract:
New hormonal therapies have enriched the therapeutic armamentarium for patients with castration-resistant prostate cancer (CRPC). Fatigue is one of the most common adverse events registered in phase III trials of these new drugs. The aim of this article is to perform a meta-analysis based on all available literature data focused on the risk rate (RR) of fatigue from new hormonal agent-based therapy in patients with CRPC. A total of 11,751 cases were included from 11 randomized trials. The analysis revealed that the second generation of hormonal therapies increased the RR of any-grade fatigue (RR = 1.27) and grade 3-4 fatigue (RR = 1.25). This last adverse event was always higher in a pre-chemotherapy setting. In conclusion, given the limitations of a literature-based study, rather than a meta-analysis based on individual patients' data, our study confirmed the increase in the RR for any-grade and grade 3-4 fatigue during the second generation of hormonal therapies, with particular attention being paid to grade 3-4 in the pre-chemotherapy setting of the disease.
More Related Videos
Related Concept Videos
Types of Hormones
Plant Hormones
Hormonal Regulation
Hormonal Regulation
Fatigue
Analysis of Population Pharmacokinetic Data

